Summary: Medscape speaks with Allison Feduccia, Ph.D., of MAPS Public Benefit Corporation about study results from six of MAPS’ Phase 2 clinical trials researching MDMA combined with psychotherapy for treating PTSD. “The findings were very remarkable. The treatment is not only durable, but patients continue to improve during the year that followed,” explains Feduccia. “We think this is because of the healing that has taken place during the psychotherapy sessions. People are able to go back to their jobs or improve their relationships. We see it as not a long-term treatment but more of an intensive psychotherapy, catalyzed by the MDMA, which allows them to overcome PTSD.”
Read the full article here.
